Ecnoglutide Phase 3 Trial in Obese Knee Osteoarthritis Registered

On July 29, 2026, a new clinical trial listing for ecnoglutide was posted on ClinicalTrials.gov. The study, titled "A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)," is registered under identifier NCT07734311. The trial is designated as Phase 3. Its current status is listed as not yet recruiting, meaning participant enrollment has not begun as of the listing date. Ecnoglutide remains classified as an unapproved compound under research investigation. No outcome data, efficacy findings, or safety results are included in this registration update. The listing establishes the trial's design phase and target population, obese participants with knee osteoarthritis, without providing further detail on enrollment timelines or study completion. As with all trial registrations, details such as recruitment start dates and site locations may be updated as the study progresses. Readers should note that a Phase 3 designation indicates a later stage clinical trial but does not by itself indicate any conclusions about the compound's effects. For more background on ecnoglutide, see the compound overview.